Terazosin And Metabolic Energetics in Parkinson's Disease

Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07464028

Acronym

TAME-PD:

Enrollment

120

Registered

2026-03-11

Start date

2026-07-01

Completion date

2031-07-01

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease (PD)

Brief summary

This study investigates if Terazosin can improve metabolism in PD.

Interventions

DRUGTerazosin 5 MG

This drug increases glycolysis in Parkinson's disease.

DRUGPlacebo

Placebo control for Terazosin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

Parkinson's disease

Design outcomes

Primary

Measure	Time frame	Description
ATP	at 1.5 year	Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years

Contacts

CONTACTNandakumar Narayanan, MD

nandakumar-narayanan@uiowa.edu+1 319 353 5698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026